A chronic angiotensin II/phenylephrine infusion mouse model provides a simple and robust tool for investigating HFpEF pathogenic mechanisms, diagnostic markers, and drug discovery.
Heart failure with preserved ejection fraction (HFpEF) is an emerging epidemic affecting up to half of patients with heart failure. Here we used a chronic angiotensin II/phenylephrine (ANG II/PE) infusion model and instituted an updated algorithm for HFpEF assessment. Given the simplicity in generating this model, it may become a useful tool for investigating pathogenic mechanisms, identification of diagnostic markers, and for drug discovery aimed at both prevention and treatment of HFpEF.
Matsiukevich et al. (Fri,) conducted a other in Heart failure with preserved ejection fraction (HFpEF). Chronic angiotensin II/phenylephrine (ANG II/PE) infusion was evaluated. A chronic angiotensin II/phenylephrine infusion mouse model provides a simple and robust tool for investigating HFpEF pathogenic mechanisms, diagnostic markers, and drug discovery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: